Campylobacteremia in stage IV gliosarcoma with bevacizumab treatment

Liu, Ping

doi:10.3402/jchimp.v2i1.17217

Cited by 4 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is only one report 1 3 describing GBS following bevacizumab administration in a patient with gliosarcoma. However, in that case, Campylobacter jejuni infection due to slight leucocytopenia caused GBS [19]. In our case, there were no signs of infection.…”

Section: Discussioncontrasting

confidence: 46%

Guillain–Barré syndrome in a cancer patient treated with bevacizumab

Taguchi¹,

Kamada²,

Yoshida³

et al. 2018

Int Canc Conf J

View full text Add to dashboard Cite

We describe a case of Guillain-Barré syndrome (GBS) in a patient treated with bevacizumab. Our case is a 60-year-old woman with Stewart-Treves syndrome (STS), and angiosarcoma of her left forearm, with onset 12 years after diagnosis with stage IIIA left breast cancer. She suffered from repeated distal metastases including skin, bone, and liver metastases. She underwent numerous treatments including left arm amputation, radiation, and chemotherapy, but her disease was resistant. Thereafter, she received bevacizumab. Two weeks following the first administration, she presented in poor physical condition. Although the cause was not specified at that time, bevacizumab was discontinued. At 1 month following first bevacizumab administration, she gradually developed dyspnea, and numbness in her tongue and hands. Soon after, she was emergently admitted to the hospital due to hyperventilation syndrome. On hospital day 4, she developed quadriparesis, and on hospital day 8, she was diagnosed with GBS following neurological testing. Treatment with intravenous immunoglobulins was started immediately upon diagnosis, and her neurological symptoms eventually resolved. A repeat challenge course of bevacizumab was avoided. Five months later, the patient perished from STS progression. GBS associated with malignancies and/or chemotherapies has been rarely described in patients with malignant lymphomas. Of note, there is only one reported case of GBS with bevacizumab. Furthermore, in some cases, GBS is lethal, and it should be considered in the differential diagnosis of patients treated with bevacizumab.

show abstract

Section: Discussioncontrasting

confidence: 46%

Guillain–Barré syndrome in a cancer patient treated with bevacizumab

Taguchi¹,

Kamada²,

Yoshida³

et al. 2018

Int Canc Conf J

View full text Add to dashboard Cite

show abstract

“…Bacteraemia due to Bacteroides fragilis [36] and Campylobacter spp. [37] was reported, Bevacizumab is a humanized IgG1 monoclonal antibody targeting VEGF-A (the most biologically active of the VEGF family members). Ramucirumab is a humanized IgG1 monoclonal antibody targeting VEGFR-2, therefore impeding the binding of VEGF-A (VEGF-B and PlGF bind only to VEGFR-1).…”

Section: Available Clinical Datamentioning

confidence: 99%

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)

Aguilar-Company

Fernández‐Ruiz

García‐Campelo

et al. 2018

Clinical Microbiology and Infection

View full text Add to dashboard Cite

show abstract

Campylobacter colibacteraemia: how common is it?

Pisipati

Zafar

2020

BMJ Case Rep

View full text Add to dashboard Cite

Campylobacter species are known to cause enteritis. However, over the past 40–50 years, there have been reports of varying presentations, such as cellulitis, spondylodiscitis and bacteraemia. Of the Campylobacter species, Campylobacter jejuni is the most common culprit for causing bacteraemia, however, Campylobacter coli bacteraemia is becoming more prevalent. Here, we discuss an unusual case of C. coli bacteraemia in a patient with decompensated liver cirrhosis.

show abstract

Campylobacteremia in stage IV gliosarcoma with bevacizumab treatment

Cited by 4 publications

References 29 publications

Guillain–Barré syndrome in a cancer patient treated with bevacizumab

Guillain–Barré syndrome in a cancer patient treated with bevacizumab

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Cell surface receptors and associated signaling pathways)

Campylobacter colibacteraemia: how common is it?

Contact Info

Product

Resources

About